More pertinent point here is Roche have another late stage clinical failure on their hands.
Add the crappy Sarepta gene therapy results...it hasn't been a great 3 months for them.
2020 was not a good year for Big Pharma to build pipeline.
I can feel a 'partnership' or strategic investment is just around the corner for ANP, Pharma need pipeline and reading the Biotech pundits, it appears M&A will increase in 2021.
More pertinent point here is Roche have another late stage...
-
- There are more pages in this discussion • 2,570 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.015(13.0%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $612.7K | 4.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56662 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 600000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |